[NCI CIRB] S1806: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer
The purpose of this study is to compare the effects, good and/or bad, of chemotherapy and radiation therapy with or without the use of atezolizumab, which is used to treat bladder cancer. The combination of chemotherapy, radiation therapy and the immunotherapy atezolizumab is considered experimental.
Muscle Invasive Bladder Cancer
Localized Muscle Invasive Bladder Cancer
Invasive Bladder Cancer
T2-T4a N0M0 urothelial carcinoma of the bladder.
Patients must be planning to receive one of the protocol specified chemotherapy regimens.
Patients must not have received any systemic chemotherapy for their bladder cancer.
Patients must not have had prior pelvic radiation.
Patients must not have received prior treatment for muscle invasive bladder cancer including neoadjuvant chemotherapy for the current tumor.
18 - 99
Healthy Volunteers Needed
Duration of Participation
5 years from study entry
Knight Cancer Institute Clinical Trials